Insulet PODD · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500
137.23
-1.96%
Close of 19 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $9.51bn
- Last close × shares
- Volume
- 1.6m
- Shares, 19 Nov 2026
- Price to earnings
- 45.0
About Insulet
From its filings with the US Securities and Exchange Commission
Insulet is based in Acton, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PODD. It is a member of the S&P 500. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $2.71bn and net income of $247.1m. At that date it held total assets of $3.19bn and shareholders' equity of $1.52bn. By region, U.S. accounted for 72.2%, followed by International at 27.9%.
Insulet Corporation (“we” or the “Company”) is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod® 5 Automated Insulin Delivery System (“Omnipod 5”), the Omnipod DASH® Insulin Management System (“Omnipod DASH”), and the Omnipod Insulin Management System (“Classic Omnipod”).
We also produce pods for Amgen for use in the Neulasta® Onpro® kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Diabetes is a chronic, life-threatening disease for which there is no known cure. It is caused by the body’s inability to produce or effectively utilize the hormone insulin, which prevents the body from adequately regulating blood glucose levels. Glucose, the primary source of energy for cells, must be maintained at certain concentrations in the blood in order to permit optimal cell function and health. In people with diabetes, blood glucose levels fluctuate between very high levels, a condition known as hyperglycemia, and very low levels, a condition called hypoglycemia. Hyperglycemia can lead to serious short-term complications, such as confusion, vomiting, dehydration, and loss of consciousness and long-term complications, such as blindness, kidney disease, nervous system disease, occlusive vascular diseases, stroke, cardiovascular disease, or death. Hypoglycemia can lead to confusion, loss of consciousness, or death.
Quoted from its 10-K, filed 18 Feb 2026. Read the filing on SEC.gov ↗
How it makes its money
Revenue, year to 31 Dec 2025
- Total Omnipod products $2.67bn · 98.7%
- U.S. $1.92bn · 70.9%
- International $754.3m · 27.9%
- Drug Delivery $34.1m · 1.3%
Latest on Insulet
Our reporting
Next results
Due on 17 Feb 2027. Analysts expect earnings of 1.74 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is Insulet's ticker?
Insulet trades as PODD on its US listing, under ISIN US45784P1012.
What was Insulet's last closing price?
137.23 on 19 Nov 2026. The figure is in USD and is never converted.
When does Insulet next report results?
Results are expected on 17 Feb 2027, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.